Overview

Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The is a multi-center, randomized, open-label, active-controlled, parallel-group comparative study (24-week treatment period). The objective of this study is to prove the superiority of BAY 86-5300 with flexible extended regimen for treatment of dysmenorrhea to BAY 86-5300 with 28-day cyclic regimen in terms of primary efficacy variable, number of days with dysmenorrheic pain over 140 days of evaluation period. In addition, the long-term safety of the flexible extended regimen of BAY86-5300 in patients treated for one year will be investigated.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Drospirenone
Ethinyl Estradiol